Identification of predictive biomarkers such as programmed death‐ligand 1 (PD‐L1) expression, microsatellite instability (MSI), and tumor mutational burden (TMB) helps guide ICI use, but need remains in further refining treatment strategies before and during treatment [3, 4, 5]. The gene discussed is CD274; the disease is neoplasm.